Eckert & Ziegler BEBIG : Changes to the Board of Directors. Capital increase by contribution in cash
(Thomson Reuters ONE) -
Press Release
REGULATED INFORMATION
Eckert & Ziegler BEBIG: Changes to the Board of Directors - Prof. Dr. Lutz
Uharek and Dr. Harald Hasselmann elected as new Board of Directors members.
Capital increase by contribution in cash with cancellation of the preferential
rights of the current shareholders, authorized capital and reverse stock split
Seneffe, June 9, 2016. Eckert & Ziegler BEBIG SA has two new Board of Directors
members. Prof. Dr. Lutz Uharek was elected to be a new member of the Board of
Directors at today's Annual General Meeting in Seneffe (Belgium). The physician
follows Martin Hölscher, whose time in office has ended after two terms in
accordance with the Articles of Association. "We would like to thank
Mr. Hölscher for the excellent and trustful working relationship and are pleased
to have found in Professor Uharek a qualified successor with comprehensive
medical expertise," said Dr. Andreas Eckert, Chairman of the Board of Directors
of Eckert & Ziegler BEBIG SA
Prof. Uharek is a hematology oncologist and a chief resident at the Medical
Department, Division of Hematology, Oncology and Tumor Immunology at the Charité
Campus Virchow Klinikum in Berlin. As an expert in the field of stem cell
transplantation and clinical cell therapy, and as the head of scientific working
groups and a principal investigator in phase I and II studies, he has extensive
expertise in translational research and the early clinical use of cellular
immunotherapeutics.
The Annual General Meeting also elected Dr. Harald Hasselman, who has been with
the company since October 2015, to the Board of Directors. He follows Dr. Edgar
Löffler, who remains a Managing Director, but is leaving the Board of Directors
at his own request. "Over the past eight years, Dr. Löffler has played an
instrumental role in driving the focus toward being a complete provider of
brachytherapy. We would like to thank him for this, and we are pleased that he
will continue to support the company on its growth course in his role as member
of the management committee," said Dr. Andreas Eckert, Chairman of the Board of
Directors of Eckert & Ziegler BEBIG SA.
An Extraordinary General Meeting, that followed the Annual General Meeting,
decided to increase its capital by way of a contribution in cash with
cancellation of the preferential right of the current shareholders for an amount
of EUR 5,056,168.48, of which EUR 3,560,771.10 EUR is allocated to the share
capital and EUR 1,495,397.38 as share premium. The beneficiary of the
cancellation of the preferential rights is the company under German law, Eckert
& Ziegler EZAG AG, i.e. the controlling shareholder of the company.
In accordance with Article 598 of the Company Code, the board of directors
decided that the issue price shall amount to EUR 0.88 per new share (i.e. the
average trading price of the 30 last days) and as a result of the capital
increase decided today, 5,745,646 new shares, without nominal value, were
issued, as compensation for the above-mentioned contribution and the share
capital of the company was increased to bring it from EUR 10,879,026.72 to EUR
14,439,797,82 EUR
The extraordinary general meeting of shareholders also decided to resolve on (i)
a reverse stock split with a ratio of ten (10) existing shares to one (1)
share, with a delegation of powers granted to the board of directors to
implement this reverse stock split and (ii) the renewal the authorisation
granted to the board of directors to increase the share capital of the company
(authorised capital).
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB) is
a European-based group active in the medical device segment of the health care
industry. Its core business is the production and distribution of medical
products for the treatment of cancer using brachytherapy. The company's
headquarters are in Belgium, with production facilities in Germany and in the
USA, as well as subsidiaries throughout Europe, the USA, India and Brazil. In
addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and
agents to support the international marketing and distribution of its product
line. The company's products and equipment are intended for use by oncologists,
radiotherapists, urologists, ophthalmologists and medical physicists. Eckert &
Ziegler BEBIG employs approximately 140 people. The company has been listed on
the Euronext stock exchange since April 1997.
Contact:
Eckert & Ziegler BEBIG SA
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir(at)bebig.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via GlobeNewswire
[HUG#2019350]
Unternehmensinformation / Kurzprofil:
Datum: 09.06.2016 - 15:42 Uhr
Sprache: Deutsch
News-ID 476800
Anzahl Zeichen: 5664
contact information:
Town:
Seneffe
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 327 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG : Changes to the Board of Directors. Capital increase by contribution in cash"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
